Weight loss options expanding for obese teens.

A clinical study published in the medical journal Obesity found that 44.9% of adolescents who received a weekly dose of semaglutide were no longer considered clinically obese. The study suggests that medical professionals should consider semaglutide treatment, especially for severely obese teens as they are less likely to respond to just therapy focused on their lifestyles. Semaglutide mimics the GLP-1 hormone, which sends a signal to the brain that the person is full. Childhood obesity is a major concern in the U.S. with more than 14 million children considered obese.